CYTH News and Press, Cyclo Therapeutics Inc. From 11/22/23

2023-11-22 10:00:14 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) to be highlighted in a platform presentation Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the &#...

Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) Merger with Applied Molecular Transport, Inc. (“AMT”) on track to close before year...

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...

Cyclo Therapeutics Inc. (CYTH) is expected to report for Q1 2024

2023-11-08 13:40:12 ET Gainers: Tenon Medical ( TNON ) +37% . Blade Air Mobility ( BLDE ) +32% . Novo Integrated Sciences ( NVOS ) +29%. Therealreal ( REAL ) +27% . ShiftPixy ( PIXY ) +20% . American Public Education ( APEI )...

NEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023. “During fiscal 2023, we made meaningful progress toward expan...

Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to develop...

Live webcast presentation on Thursday, October 12 th at 12:00 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science...

Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 ...